HIV-1 virus-like particles bearing pure env trimers expose neutralizing epitopes but occlude nonneutralizing epitopes. - Wikidata - wikimedia - TriplyDB

HIV-1 virus-like particles bearing pure env trimers expose neutralizing epitopes but occlude nonneutralizing epitopes.

HIV-1 virus-like particles bearing pure env trimers expose neutralizing epitopes but occlude nonneutralizing epitopes.

http://www.wikidata.org/entity/Q39402539

about

Current Advances in Virus-Like Particles as a Vaccination Approach against HIV Infection HIV-1 neutralizing antibodies: understanding nature's pathways Vaccine-Elicited Tier 2 HIV-1 Neutralizing Antibodies Bind to Quaternary Epitopes Involving Glycan-Deficient Patches Proximal to the CD4 Binding Site Crystal structure, conformational fixation and entry-related interactions of mature ligand-free HIV-1 Env Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120 Autoreactivity and Exceptional CDR Plasticity (but Not Unusual Polyspecificity) Hinder Elicitation of the Anti-HIV Antibody 4E10 Allosteric modulation of the HIV-1 gp120-gp41 association site by adjacent gp120 variable region 1 (V1) N-glycans linked to neutralization sensitivity A Novel Two-Tag System for Monitoring Transport and Cleavage through the Classical Secretory Pathway - Adaptation to HIV Envelope Processing Humanized Immunoglobulin Mice: Models for HIV Vaccine Testing and Studying the Broadly Neutralizing Antibody Problem.A human antibody to the CD4 binding site of gp120 capable of highly potent but sporadic cross clade neutralization of primary HIV-1.Estimating the probability of polyreactive antibodies 4E10 and 2F5 disabling a gp41 trimer after T cell-HIV adhesion.Multi-Parameter Exploration of HIV-1 Virus-Like Particles as Neutralizing Antibody Immunogens in Guinea Pigs, Rabbits and Macaques Reducing V3 Antigenicity and Immunogenicity on Soluble, Native-Like HIV-1 Env SOSIP Trimers Elicitation of HIV-1-neutralizing antibodies against the CD4-binding site.A novel, live-attenuated vesicular stomatitis virus vector displaying conformationally intact, functional HIV-1 envelope trimers that elicits potent cellular and humoral responses in mice.Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface.Inhibition of HIV Entry by Targeting the Envelope Transmembrane Subunit gp41.Increased functional stability and homogeneity of viral envelope spikes through directed evolution.Pre-clinical development of a recombinant, replication-competent adenovirus serotype 4 vector vaccine expressing HIV-1 envelope 1086 clade C.Single-Chain Soluble BG505.SOSIP gp140 Trimers as Structural and Antigenic Mimics of Mature Closed HIV-1 Env.Strategies to guide the antibody affinity maturation process Discrete partitioning of HIV-1 Env forms revealed by viral capture.Effects of partially dismantling the CD4 binding site glycan fence of HIV-1 Envelope glycoprotein trimers on neutralizing antibody induction.Chemical Cross-Linking Stabilizes Native-Like HIV-1 Envelope Glycoprotein Trimer Antigens M48U1 CD4 mimetic has a sustained inhibitory effect on cell-associated HIV-1 by attenuating virion infectivity through gp120 shedding.Native Conformation and Canonical Disulfide Bond Formation Are Interlinked Properties of HIV-1 Env Glycoproteins.Inhibition of the HIV-1 spike by single-PG9/16-antibody binding suggests a coordinated-activation model for its three protomeric units Development of prophylactic vaccines against HIV-1.Presenting native-like trimeric HIV-1 antigens with self-assembling nanoparticles Impact of HIV-1 Membrane Cholesterol on Cell-Independent Lytic Inactivation and Cellular Infectivity.Modeling virus- and antibody-specific factors to predict human immunodeficiency virus neutralization efficiency.Native-like Env trimers as a platform for HIV-1 vaccine design.Humoral immunity in the Friend retrovirus infection model.Antibody-based candidate therapeutics against HIV-1: implications for virus eradication and vaccine design.Vaccine design: emerging concepts and renewed optimism.HIV-1 vaccine immunogen design strategies.Envelope Glycoprotein Trimers as HIV-1 Vaccine Immunogens HIV-1 envelope glycoprotein immunogens to induce broadly neutralizing antibodies.Improving the Expression and Purification of Soluble, Recombinant Native-Like HIV-1 Envelope Glycoprotein Trimers by Targeted Sequence Changes.

P2860

Q26775082-AA9A6BC0-5510-4BA9-AC7C-8B3BB0B3F42F Q27000480-8529F28E-DE22-4F68-95E9-E4C0868E8999 Q27319450-855D1CAE-D2D5-4D58-9D85-62D2E5AD5DE6 Q27644383-1BF591F8-91D1-4EFC-86C3-2B76F6C8EC8B Q27644515-E2C8B7FB-0B9F-461C-8F1E-B6011CB9204D Q27678306-335A4DE7-3333-49F8-8CA4-B15E19C7B382 Q27680125-ACC9E629-B06E-44A9-818D-2EBE44B0A211 Q28485983-720CAD72-D863-40EA-BC67-56A59E2B0844 Q28533980-3224E425-5C6D-460E-A373-CEF17737023F Q30234773-858035A9-AD9C-4A86-8D75-98DD77B2B6AD Q31132248-94036C50-3AA0-4A4D-B0C0-0DB0EB7DE024 Q31151010-698FD7F5-CB5E-46C8-BA59-B801AB940709 Q33683203-369D4F48-FF48-49EA-8B6B-CC5C3ED1AE80 Q33907694-3662E35B-61D0-46C6-A54A-7FC8CFB44F55 Q34133551-3D9726AD-8F45-4C48-9031-07E304519F75 Q34172295-21D85F85-BFA5-46A2-8777-F21B5D10540E Q34473958-23C99AC3-7CA4-4C95-92FF-0A76FA2B9761 Q34517381-F7EF586F-8D36-451D-8DA5-4B44AFB8CF50 Q34611144-EDF000FA-4DFF-4388-BB30-ACAC75D833A5 Q35061529-F9D66591-89E0-4D6B-AC72-D6B12098B799 Q35641498-7D2064F0-AAC3-4869-B0AB-233135E5920D Q35685300-7656E846-7F94-4ACB-AAD3-1BDB7ADCAFC1 Q36088254-4986B0D3-7CBA-48FE-BE71-983F163BD5E4 Q36303368-76B6DAAC-0E2A-49C6-8764-8D09EEC2E3A2 Q36434196-B5E059D9-A505-4330-AC72-67F8C367968C Q36608485-F2B1C239-F429-417F-B9CA-6E4C0D9D3DAC Q36736597-8BCB0249-BB7F-44DA-B1A8-6E8FAB19CC6D Q36911746-5154B62C-EA4E-49F1-8E13-7D9A3880DB33 Q37042563-8723E369-279D-43BB-B05F-86C8B5CB37CF Q37060947-3ACF3A54-4D6A-45EC-8729-1EBBFD7CBBE1 Q37183472-B26AC27E-A139-4065-9845-0BDAF33EF1AA Q37419199-FD5C775E-68C0-4478-80B0-BFB161E02A29 Q37633417-BC5619F9-A0D6-4417-BD09-21A3B51E899E Q37730925-E36CC765-1EC7-42A5-AC8C-DF65F75C0DBA Q38072056-D04BB01C-D47A-4676-82D0-837DB38AA26C Q38087785-A4AEF713-ADD1-4186-BBDD-BCF9143755F6 Q38330424-5AC01D8F-78DF-4C5A-938E-A563CC2C66EC Q38581943-A9515DC4-9AFA-4E5B-B40A-D2A04EAA6322 Q38665463-0D27E20E-0DC9-4329-8D06-CDD34B9781A3 Q38708708-19C51391-DDF9-411D-AF0A-A070B7950274

P2860

HIV-1 virus-like particles bearing pure env trimers expose neutralizing epitopes but occlude nonneutralizing epitopes.

http://www.wikidata.org/entity/Q39402539

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

HIV-1 virus-like particles bea ...... lude nonneutralizing epitopes.

@en

HIV-1 virus-like particles bea ...... lude nonneutralizing epitopes.

@nl

type

label

HIV-1 virus-like particles bea ...... lude nonneutralizing epitopes.

@en

HIV-1 virus-like particles bea ...... lude nonneutralizing epitopes.

@nl

prefLabel

HIV-1 virus-like particles bea ...... lude nonneutralizing epitopes.

@en

HIV-1 virus-like particles bea ...... lude nonneutralizing epitopes.

@nl

P1433

Q39402539-77254A2E-CD9F-46CB-B393-4F38DCB9A76A

P1476

Q39402539-7517601B-DCA3-4976-8F14-6FABD3D98231

P2093

Q39402539-39DB5D62-3E22-4CE4-9588-D7555CC416F4

Q39402539-C4DA0070-0BA6-4051-B70F-377E126632EE

Q39402539-D82E34ED-1934-45A0-BA21-7074B46FE14A

Q39402539-DCBF774D-3B74-42BF-86F7-FFAFAA17BE68

P2860

Q39402539-00FA7FC6-AAA4-48E7-A2E8-EDC3191FA418

Q39402539-06C52B80-49C9-4C99-B96D-5D2AA43BA933

Q39402539-085345D9-D166-43E9-9247-11E25F8CE6BF

Q39402539-09CFEAFE-3C01-409E-B53A-4FF4FD7D405A

Q39402539-1278439A-CDBB-444A-AF51-C1F8FC0980FC

Q39402539-1AB09686-7F76-4163-85CA-68820EC4412C

Q39402539-1AE729A1-2AA0-4CE1-81C5-11530704D7C5

Q39402539-1D37C9DC-3E2C-42FB-BBA3-756C0815D11A

Q39402539-29037EE7-84F3-496C-937A-313FE183C886

Q39402539-2B1B4EC5-CE37-4D49-890D-5793D422192A

P304

Q39402539-4EDFEAB3-009D-4F5C-B6C5-8F7B96BF80AD

P31

Q39402539-00478F85-68DA-47BB-A409-A314D10812EE

P356

Q39402539-851577CF-90A9-4A3E-A6ED-4678F0D511FA

P407

Q39402539-27D5576D-9290-46E5-9CE2-4CD0DB6DB9F9

P433

Q39402539-2760DA0C-77F8-4733-A3D4-D815A4E071A5

P478

Q39402539-96BF9AB8-C0CF-41D3-B569-0B46264ABCED

P577

Q39402539-A73B3C81-1B39-46B9-8B0A-24F5DF7F0762

P698

Q39402539-1485EBB9-A32E-4987-AB5C-879326C294E9

P932

Q39402539-FDCD274A-EE55-4DD5-ACEF-FB9921D4DCB5

P356

P1433

Journal of Virology

P1476

HIV-1 virus-like particles bea ...... lude nonneutralizing epitopes.

@en

P2093

Ema T Crooks

http://www.w3.org/2001/XMLSchema#string

James M Binley

http://www.w3.org/2001/XMLSchema#string

Keiko Osawa

http://www.w3.org/2001/XMLSchema#string

Tommy Tong

http://www.w3.org/2001/XMLSchema#string

P2860

Effects of inefficient cleavage of the signal sequence of HIV-1 gp 120 on its association with calnexin, folding, and intracellular transport

Biosynthesis and processing of human immunodeficiency virus type 1 envelope glycoproteins: effects of monensin on glycosylation and transport

Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates

Antibody domain exchange is an immunological solution to carbohydrate cluster recognition

HIV-1 broadly neutralizing antibody extracts its epitope from a kinked gp41 ectodomain region on the viral membrane

Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding

A Potent and Broad Neutralizing Antibody Recognizes and Penetrates the HIV Glycan Shield

Functional stability of unliganded envelope glycoprotein spikes among isolates of human immunodeficiency virus type 1 (HIV-1)

Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target

Broad neutralization coverage of HIV by multiple highly potent antibodies

P304

3574-3587

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/JVI.06938-11

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

86

http://www.w3.org/2001/XMLSchema#string

P577

2012-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22301141

http://www.w3.org/2001/XMLSchema#string

P932

3302546

http://www.w3.org/2001/XMLSchema#string